Hypolipidemic activity of 18β-glycyrrhetinic acid on streptozotocin-induced diabetic rats

European Journal of Pharmacology

Volumn 612, Issue 1-3, 2009, Pages 93-97

  Kalaiarasi, Panneerselvam ^a   Kaviarasan, Kuppuswamy ^a   Pugalendi, Kodukkur Viswanathan ^a  

^a ANNAMALAI UNIVERSITY   (India)

Author keywords

18 glycyrrhetinic acid; Diabetes; Lipid profile; Streptozotocin

Indexed keywords

FATTY ACID; GLIBENCLAMIDE; GLYCYRRHETINIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STREPTOZOCIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; 18ALPHA GLYCYRRHETINIC ACID; 18ALPHA-GLYCYRRHETINIC ACID; ANTIDIABETIC AGENT; CHOLESTEROL; DRUG DERIVATIVE; LIPID; LIPOPROTEIN; PHOSPHOLIPID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; HEART; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPOLIPEMIA; KIDNEY; LIPID BLOOD LEVEL; LIPID LIVER LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RISK REDUCTION; STREPTOZOCIN DIABETES; TISSUE LEVEL; ANIMAL; BLOOD; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; LIPID METABOLISM; LIVER; METABOLISM; RANDOMIZATION;

ANIMALS; BLOOD GLUCOSE; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, NONESTERIFIED; GLYCYRRHETINIC ACID; HEART; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; KIDNEY; LIPID METABOLISM; LIPIDS; LIPOPROTEINS; LIVER; MALE; MOLECULAR STRUCTURE; PHOSPHOLIPIDS; RANDOM ALLOCATION; RATS; STREPTOZOCIN; TRIGLYCERIDES;

EID: 65549167998     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.04.003     Document Type: Article

References (41)

1. Abe N., Ebina T., and Ishida N. Interferon induction by glycyrrhizin and glycyrrhetinic acid in mice. Microbiol. Immunol. 26 (1982) 535-539
2. Andrade-Cetto A., and Wiedenfeld H. Hypoglycemic effect of Acosmium panamense bark on streptozotocin diabetic rats. J. Ethnopharmacol. 90 (2004) 217-220
3. Ao Y., Chen J., Yue J., and Peng R.X. Effects of 18a-glycyrrhizin on the pharmacodynamics and pharmacokinetics of glibenclamide in alloxan-induced diabetic rats. European. J. Pharmacol. 587 (2008) 330-335
4. Armanini D., De Palo C.B., Mattarello M.J., Spinella P., Zaccaria M., Ermolao A., Palermo M., Fiore C., Sartorato P., Francini-Pesenti F., and Karbowiak I. Effect of licorice on the reduction of body fat mass in healthy subjects. J. Endocrinol. Invest. 26 (2003) 646-650
5. Bergmeyer H.U. Glucose 6-phosphate dehydrogenase. In: Bergmeyer H.U. (Ed). Methods of Enzymatic Analysis vol. 2 (1984), Verlag Chemie, Weinheim, Germany 222-223
6. Betteridge J. Lipid disorders in diabetes mellitus. In: Pickup J.C., and Williams G. (Eds). Textbook of Diabetes (1997), Blackwell Science, London 1-35
7. Braun J.E., and Severson D.L. Regulation of the synthesis, processing and translocation of lipoprotein lipase. Biochem. J. 287 (1992) 337-347
8. Burgi W., Briner M., Franken N., and Kessler A.C.H. One step sandwich enzyme immunoassay for insulin using monoclonal antibodies. Clin. Biochem. 21 (1988) 311-314
9. Doll R., Hill I.D., Hutton C., and Underwood D.J. Clinical trial of a triterpenoids liquorice compound in gastric and duodenal ulcer. Lancet 2 (1962) 793-796
10. Falholt K., Falholt W., and Lund B. An easy colorimetric micromethod for routine determination of free fatty acids in plasma. Clin. Chim. Acta 46 (1973) 105-111
11. Folch J., Lees M., and Solane S.G.H. A simple method for isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226 (1957) 497-509
12. Fontbonne A., Eschwege E., Cambien F., Richard J.L., Ducimetiere P., Thibult N., Warnet J.M., Claude J.R., and Rosselin G.E. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Diabetologia 32 (1989) 300-304
13. Foster L.B., and Dunn R.T. Stable reagents for determination of serum triglycerides by colorimetric hantzsch condensation method. Clin. Chem. 19 (1973) 338-340
14. Friedwald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of LDL-C in plasma without use of the preparative ultracentrifuge. Clin. Chem. 18 (1972) 449-502
15. Goodman L.S., and Gilman A. The Pharmacological Basis of Therapeutics. 7th ed. (1985), MacMillan, New York 490
16. Grudy M.S., Benjamin I.J., Burke G.L., Chait A., Eckel R.H., and Howard B.V. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100 (1999) 1134-1146
17. Horigome H., Hirano T., and Oka K. Therapeutic effect of glycyrrhetinic acid in MRL lpr/lpr mice: implications of alteration of corticosteroid metabolism. Life Sci. 69 (2001) 2429-2438
18. Ito M., Sato A., Hirabayashi K., Tanabe F., Shigeta S., Baba M., and De Clercq E. Nakashima H, Yamamoto N. Mechanism of inhibitory effect of glycyrrhizin on replication of human immunodeficiency virus (HIV). Antiviral. Res. 10 (1988) 289-298
19. Kiso Y., Tohkin M., Hikino H., Hattori M., Sakamoto T., and Namba T. Mechanism of antihepatotoxic activity of glycyrrhizin. I: effect of free radical generation and lipid peroxidation. Planta. Med. 50 (1984) 298-302
20. Ko B.S., Jang J.S., Hong S.M., Sung S.R., Lee J.E., Lee M.Y., Jeon W.K., and Park S. Changes in components, glycyrrhizin and glycyrrhetinic acid in raw Glycyrrhiza uralensis fisch, modify insulin sensitizing and insulinotropic actions. Biosci. Biotechnol. Biochem. 71 (2007) 1452-1461
21. Krähenbühl S., Hasler F., Frey B.M., Frey F.J., Brenneisen R., and Krapf R. Kinetics and dynamics of orally administered 18 beta-glycyrrhetinic acid in humans. J. Clin. Endocrinol. Metab. 78 (1994) 581-585
22. Krähenbühl S., Hasler F., and Krapf R. Analysis and pharmacokinetics of glycyrrhizic acid and glycyrrhetinic acid in humans and experimental animals. Steroids 59 (1994) 121-126
23. Kudchodkar B.J., Lee M.J., Lee S.M., DiMarco N.M., and Lacko A.G. Effect of dietary protein on cholesterol homeostasis in diabetic rats. J. Lipid. Res. 10 (1988) 1272-1287
24. Lopez-Virella M.F., Wholtmann H.J., Mayfield R.K., Loadholt C.B., and Colwell J.A. Effect of metabolic control on lipid, lipoprotein, and apolipoprotein levels in 55 insulin-dependent diabetic patients: a longitudinal study. Diabetes 32 (1983) 20-25
25. Lusis J.A. Atheroscelerosis. Nature 407 (2000) 233-241
26. Motta M., Giugno I., Bosco S., Pistone G., Ruello P., Maugeri D., and Malaguarnera M. Serum lipoprotein (a) changes in acute myocardial infarction. Panminerva. Med. 43 (2001) 77-80
27. Murray R.R., Granner D.K., Mayes P.A., and Rodwell V.W. Harper's biochemistry. Gluconeogenesis and the Control of Blood Glucose. 26th edition (2003), Appleton and Lange, Stanford, Connecticut 153-162
28. Nose M., Ito M., Kamimira K., Shimizu M., and Ogihara Y.A. Comparison of the antihepatotoxic activity between glycyrrhizin and glycyrrhetinic acid. Planta. Med. 60 (1994) 136-139
29. Ohuchi K., Kamada Y., Levine L., and Tsurufuji S. Glycyrrhizin inhibits prostaglandin E2 production by activated peritoneal macrophages from rats. Prostaglandins. Med. 7 (1981) 457-463
30. Okutan H., Ozcelik N., Yilmaz H.R., and Uz E. Effects of caffeic acid phenethyl ester on lipid peroxidation and antioxidant enzymes in diabetic rat heart. Clin. Biochem. 38 (2005) 191-196
31. Rhoads G.G., Gulbrandse C.L., and Kagan A. Serum lipoproteins and coronary artery diseases in a population study of Hawaii, a Japanese man. N. Engl. J. Med. 294 (1976) 293-298
32. Shibayama Y. Prevention of hepatotoxic responses to chemicals by glycyrrhizin in rats. Exp. Mol. Pathol. 51 (1989) 48-55
33. Siedel J., Hagele E.O., Ziegenhorn J., and Wahlefeld A.W. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin. Chem. 29 (1983) 1075-1080
34. Singh B.M., Palma M.A., and Nattrass M. Multiple aspects of insulin resistance: comparison of glucose and intermediary metabolite response to incremental insulin infusion in IDDM subjects of short and long duration. Diabetes 36 (1987) 740-748
35. Takeda S., Ishihara K., Wakui Y., Amagaya S., Maruno M., Akao T., and Kobashi K. Bioavailability study of glycyrrhetinic acid after oral administration of glycyrrhizin in rats; relevance to the intestinal bacterial hydrolysis. J. Pharm. Pharmacol. 48 (1996) 902-905
36. Takii H., Kometani T., Nishimura T., Nakae T., Okada S., and Fushiki T. Antidiabetic effect of glycyrrhizin in genetically diabetic KK-Ay mice. Biol. Pharm. Bull. 24 (2001) 484-487
37. Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann. Clin. Biochem. 6 (1969) 24
38. Warnick G.R., Nguyen T., and Alberts A.A. Comparison of improved precipitation methods for quantification of high-density lipoprotein cholesterol. Clin. Chem. 31 (1985) 217
39. Weber G., and Convery H.J.H. Insulin: inducer of glucose 6-phosphate dehydrogenase. Life Sci. 5 (1966) 1136-1146
40. Zhang X.Y., Wu R.J., Chen J., and An D.K. Determination of glycyrrhizin and its metabolite glycyrrhetinic acid in rabbit plasma by high-performance liquid chromatography after oral administration of licorzin. J. Chromatogr. Biomed. Appl. 495 (1989) 343-348
41. Zilversmit D.B., and Davis A.K. Microdetermination of phospholipids by TCA precipitation. J. Lab. Clin. Med. 35 (1950) 155-159